title: Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: H
authors.initials: H
authors.lastname: Vioix
authors.affiliation: Costello Medical Consulting Ltd., Cambridge, UK.
authors.forename: L A
authors.initials: LA
authors.lastname: Eddowes
authors.affiliation: Costello Medical Consulting Ltd., Cambridge, UK.
authors.forename: M
authors.initials: M
authors.lastname: Griffiths
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: Z
authors.initials: Z
authors.lastname: Gabriel